{
    "nct_id": "NCT06136559",
    "official_title": "A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)",
    "inclusion_criteria": "The main inclusion criteria include but are not limited to the following:\n\n* Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy.\n* Has at least 1 marker of disease burden.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.\n* Has the ability to swallow and retain oral medication.\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.\n* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "The main exclusion criteria include but are not limited to the following:\n\n* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.\n* Has gastrointestinal (GI) dysfunction that may affect drug absorption.\n* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.\n* Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.\n* Has clinically significant cardiovascular disease.\n* Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients.\n* Has history of severe bleeding disorder.\n* Has history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.\n* Has received any systemic anticancer therapy for CLL/SLL.\n* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.\n* Has active infection requiring systemic therapy.\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.",
    "miscellaneous_criteria": ""
}